Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA3 | P07451 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22635666 | 0.91 | ALDH1A1 (0.58) | ALDH1A1NR3C2CA1CA2SMN1; SMN2 | |
| SCHEMBL27170892 | 0.89 | SMN1; SMN2 (0.73) | ALDH1A1NR3C2CA1CA2SMN1; SMN2 | |
| SCHEMBL4002880 | 0.85 | MAPT (0.68) | CA1CA2SMN1; SMN2GAACA12 | |
| SCHEMBL13588309 | 0.83 | CA1 (0.56) | CA1CA2SMN1; SMN2KIF11CA12 | |
| SCHEMBL7629070 | 0.82 | SMN1; SMN2 (0.80) | ALDH1A1NR3C2CA1CA2SMN1; SMN2 | |
| SCHEMBL8483992 | 0.81 | ALDH1A1 (1.00) | ALDH1A1NR3C2CA1CA2SMN1; SMN2 | |
| SCHEMBL24361297 | 0.80 | CA1 (0.54) | ALDH1A1CA1CA2KIF11MMP1 | |
| SCHEMBL15946356 | 0.80 | ALDH1A1 (0.56) | ALDH1A1CA1CA2SMN1; SMN2KIF11 | |
| SCHEMBL12054697 | 0.79 | CA1 (0.53) | CA1CA2SMN1; SMN2KIF11CA12 | |
| SCHEMBL22446711 | 0.79 | CA1 (0.53) | CA1CA2SMN1; SMN2KIF11CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547204-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer Intellectual Property GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | claimed |
| WO-2011113861-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | WO | claimed |
| US-20250236616-A1 | IMMUNOMODULATING AZALIDES | ZOETIS SERVICES LLC | 2025-07-24 | — | — | US | disclosed |
| CN-118223046-A | Electrochemical preparation method of oxazoline compound containing sulfonamide group | 华南理工大学 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023177877-A1 | RALINEPAG PRODRUGS AND USES THEREOF | UNITED THERAPEUTICS CORPORATION (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023086417-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-110857278-B | Method for synthesizing N-methylsulfonamide in water | 南京理工大学 | 2022-04-15 | — | — | CN | disclosed |
| CN-109420525-B | Metal iridium catalyst of 2, 2' -bis-benzimidazole ligand and method for synthesizing N-methylated primary amine by using metal iridium catalyst | 南京理工大学 | 2021-10-08 | — | — | CN | disclosed |
| CN-108707096-B | Process for preparing aminoalcohol derivatives | 上海科技大学 | 2021-03-19 | — | — | CN | disclosed |
| WO-2020182159-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | 上海华汇拓医药科技有限公司 | 2020-09-17 | — | — | WO | disclosed |
| EP-1889848-A1 | 6,7-UNSATURATED-7-CARBAMOYL SUBSTITUTED MORPHINAN DERIVATIVE | Shionogi Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007122173-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| CN-1208329-C | Novel aniline derivative | HOFFMANN LA ROCHE (CH) | 2005-06-29 | — | — | CN | disclosed |
| EP-1521746-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| CN-1604890-A | Substituted cyclohexane derivatives | HOFFMANN LA ROCHE (CH) | 2005-04-06 | — | — | CN | disclosed |
| EP-1456171-A1 | SUBSTITUTED CYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003076418-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| CN-1443179-A | Aniline derivatives | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | CN | disclosed |
| WO-2003053919-A1 | SUBSTITUTED CYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236616-A1 | IMMUNOMODULATING AZALIDES | IL2, MALT1, FCGRT | ALDH1A1 196/4885NR3C2 122/4885CA1 1803/4885 |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | STS, ARSA, TST | ALDH1A1 1980/4885NR3C2 634/4885CA1 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.